Growth hormone (GH) is a hormone necessary for the growth and development of all organs in the human body and is synthesised and secreted by the pituitary gland. Pituitary diseases can lead to abnormalities in GH secretion. The main manifestations are acromegaly and growth hormone deficiency (GHD). Abnormalities in GH secretion increase the incidence of cardiovascular disease and the risk of cardiovascular death, which reduces the survival and quality of life of patients. Therefore, it is necessary to study the effects of GH on the cardiovascular system. The relationship between GH and the cardiovascular system has attracted much attention, and this article will review the relationship between GH and the cardiovascular system.

Xuerui Xie, Wei Ren. The Research Progress of Growth Hormone and Cardiovascular Disease. International Journal of Frontiers in Medicine (2024), Vol. 6, Issue 3: 43-55. https://doi.org/10.25236/IJFM.2024.060308.

[1] Jörgen I, Michele A, Kristjan K, et al. GH and the cardiovascular system: an update on a topic at heart [J]. Endocrine,2015,48(1):25-35.

[2] Sverrisdóttir YB, Elam M, Herlitz H, et al. Intense sympathetic nerve activity in adults with hypopituitarism and untreated growth hormone deficiency. J Clin Endocrinol Metab. 1998 Jun; 83(6): 1881-5.

[3] J F S, Virginie T, Chen C, et al. Neuroendocrine Regulation of Growth Hormone Secretion[J]. Comprehensive Physiology,2016,6(2):687-735.

[4] R A N, G I R H. Growth Hormone and Insulin-Like Growth Factor-1[J]. Frontiers of hormone research, 2016,47101-14.

[5] B M R, M J W. Growth hormone - past, present and future[J]. Nature reviews. endocrinology, 2018, 14(5): 285-300.

[6] Frank J S. Classical and novel GH receptor signaling pathways[J]. Molecular and Cellular Endocrinology, 2020,518110999-999.

[7] Turyn D, Dominici FP, Sotelo AI, et al. Growth hormone-binding protein enhances growth hormone activity in vivo[J]. Am J Physiol. 1997 Sep;273(3 Pt 1): E549-56. 

[8] Kopchick J J, Andry M J. Growth Hormone (GH), GH Receptor, and Signal Transduction[J]. Molecular Genetics and Metabolism,2000,71(1-2):293-314.

[9] Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions[J]. Endocr Rev. 1995 Feb;16(1):3-34.

[10] Kölle S, Sinowatz F, Boie G. et al. Topography of growth hormone receptor expression in the bovine embryo [J]. Histochem Cell Biol. 1998 Apr;109(4):417-9.

[11] Delafontaine P, Song YH, Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels [J]. Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):435-44. 

[12] Ock S, Lee WS, Ahn J, et al. Deletion of IGF-1 Receptors in Cardiomyocytes Attenuates Cardiac Aging in Male Mice[J]. endocrinology. 2016 Jan;157(1):336-45. 

[13] Welch S, Plank D, Witt S, et al. Cardiac-specific IGF-1 expression attenuates dilated cardiomyopathy in tropomodulin-overexpressing transgenic mice[J]. Circ Res. 2002 Apr 5;90(6):641-8.

[14] Lu C, Schwartzbauer G, Sperling MA, et al. Demonstration of direct effects of growth hormone on neonatal cardiomyocytes[J]. J Biol Chem. 2001 Jun 22;276(25):22892-900.

[15] C L, G S, A M S, et al. Demonstration of direct effects of growth hormone on neonatal cardiomyocytes [J]. J Biol Chem. 2001 Jun 22;276(25):22892-900. 

[16] Ito H, Hiroe M, Hirata Y, et al. Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes[J]. Circulation. 1993 May; 87(5): 1715-21.

[17] W. K H, H. I W, Ping F, et al. Insulin-like growth factor-1 directly affects cardiac cellular remodeling via distinct pathways [J]. IJC Heart Vasculature,2021,36100852-100852.

[18] Brüel A, Oxlund H. Biosynthetic growth hormone increases the collagen deposition rate in rat aorta and heart [J]. Eur J Endocrinol. 1995 Feb;132(2):195-9.

[19] Liao Y, Li H, Pi Y, et al. Cardioprotective effect of IGF-1 against myocardial ischemia/reperfusion injury through activation of PI3K/Akt pathway in rats in vivo[J]. Journal of International Medical Research,2019,47(8):3886-3897.

[20] Masato K, Toshio N, Naomichi K, et al. Pericardial Grafting of Cardiac Progenitor Cells in Self-Assembling Peptide Scaffold Improves Cardiac Function After Myocardial Infarction[J]. Cell transplantation, 2023,32 9636897231174078-9636897231174078.

[21] Freestone NS, Ribaric S, Mason WT. The effect of insulin-like growth factor-1 on adult rat cardiac contractility [J]. Mol Cell Biochem. 1996 Oct-Nov;163-164:223-9.

[22] Cittadini A, Ishiguro Y, Strömer H, et al. Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitising the myofilament to Ca2+ through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles[J]. Circ Res. 1998 Jul 13;83(1):50-9.

[23] Solem ML, Thomas AP. Modulation of cardiac Ca2+ channels by IGF1[J]. Biochem Biophys Res Commun. 1998 Nov 9;252(1):151-5.

[24] Houck WV, Pan LC, Kribbs SB, et al. Effects of growth hormone supplementation on left ventricular morphology and myocyte function with the development of congestive heart failure[J]. Circulation. 1999 Nov 9; 100(19):2003-9.

[25] Timsit J, Riou B, Bertherat J, et al. Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetics, isomyosin pattern and myosin adenosine triphosphatase activity of rat left ventricle[J]. J Clin Invest. 1990 Aug;86(2):507-15.

[26] Guolian L, Juan-Pablo R D, A L J, et al. Growth hormone exerts acute vascular effects independent of systemic or muscle insulin-like growth factor I[J]. The Journal of clinical endocrinology and metabolism,2008,93(4):1379-85.

[27] Tsukahara H, Gordienko DV, Tonshoff B, et al. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells[J]. Kidney Int. 1994 Feb;45(2):598-604.

[28] Lei J, Vodovotz Y, Tzeng E, et al. Nitric oxide, a protective molecule in the cardiovascular system[J]. Nitric Oxide,2013,35175-185.

[29] Kedar G, M H A, C A S, et al. Nitric oxide: what's new to NO? [J]. American journal of physiology. Cell physiology, 2017,312(3):C254-C262.

[30] Caicedo D, Díaz O, Devesa P, et al. Growth Hormone (GH) and Cardiovascular System[J]. International Journal of Molecular Sciences,2018,19(1):290.

[31] Young-Lai C, Sung-Mo H, Ji-Yoon K, et al. Specific activation of insulin-like growth factor-1 receptor by ginsenoside Rg5 promotes angiogenesis and vasorelaxation[J]. The Journal of biological chemistry, 2015,290(1):467-77.

[32] Patrice D, Yao-Hua S, Yangxin L. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels[J]. Arteriosclerosis, thrombosis, and vascular biology, 2004, 24(3): 435-44.

[33] D E R, Ruxandra D. Insulin-like growth factor I plasmid therapy promotes in vivo angiogenesis[J]. Molecular therapy: the journal of the American Society of Gene Therapy,2004,9(1):46-55.

[34] C L, D L, I T. Insulin-like growth factor I is required for vessel remodeling in the adult brain[J]. the United States of Ameria,2004,101(26):9833-8.

[35] J E S, L C C, S S, et al. Gene therapy vector-mediated expression of insulin-like growth factors protects cardiomyocytes from apoptosis and enhances neovascularisation[J]. American journal of physiology. Heart and circulatory physiology,2003,284(4):H1429-40.

[36] C J M, L R S, M T H, et al. Insulin-like growth factors-1 and -2, but not hypoxia, synergise with gonadotropin hormone to promote vascular endothelial growth factor-A secretion by monkey granulosa cells from preovulatory follicles[J]. Biology of reproduction,2003,68(4):1112-8.

[37] Jia G, Mitra K A, Gangahar M D, et al. Insulin-like growth factor-1 induces phosphorylation of PI3K-Akt/PKB to potentiate proliferation of smooth muscle cells in human saphenous vein[J]. Experimental and Molecular Pathology,2010,89(1):20-26.

[38] Miranda S, Ramaswamy R, Jiwang C, et al. Smooth Muscle Insulin-Like Growth Factor-1 Mediates Hypoxia-Induced Pulmonary Hypertension in Neonatal Mice[J]. American journal of respiratory cell and molecular biology,2016,55(6):779-791.

[39] Vannella M K, Wynn A T. Mechanisms of Organ Injury and Repair by Macrophages[J]. Annual Review of Physiology,2017,79(1):593-617.

[40] Furundzija V, Fritzsche J, Kaufmann J, et al. IGF-1 increases macrophage motility via PKC/p38-dependent alphavbeta3-integrin inside-out signaling[J]. Biochem Biophys Res Commun. 2010 Apr 9; 394(3):786-91.

[41] Wanying T, Ming Z, Yu W, et al. IGF  1 inhibits palmitic acid  induced mitochondrial apoptosis in macrophages[J]. Molecular medicine reports, 2023, 28(6).

[42] Elijah IE, Branski LK, Finnerty CC, et al. The GH/IGF-1 system in critical illness[J]. Best Pract Res Clin Endocrinol Metab. 2011 Oct;25(5):759-67. 

[43] Sukhanov S, Snarski P, Vaughn C, et al. Insulin-like growth factor I reduces lipid oxidation and foam cell formation via downregulation of 12/15- lipoxygenase[J]. Atherosclerosis,2015,238(2):313-320.

[44] Bergmann Y S, Mikael E, Kenneth C, et al. The effect of growth hormone (GH) replacement therapy on sympathetic nerve hyperactivity in hypopituitary adults: a double-blind, placebo-controlled, crossover, short-term trial followed by long-term open GH replacement in hypopituitary adults[J]. Journal of hypertension,2003,21(10):1905-14.

[45] B C, G L, V R, et al. Muscle sympathetic nerve activity in patients with acromegaly[J]. J Clin Endocrinol Metab. 2000 Sep;85(9):3203-7. 

[46] P R C O, A R M, H M A, et al. Emerging role of the GH/IGF-I on cardiometabolic control[J]. Arquivos brasileiros de cardiologia,2011,97(5):434-9.

[47] Duan Tingting. Effect of rhGH treatment on lipid metabolism in children with GHD and evaluation of efficacy [D]. Chengde Medical College, 2020.

[48] Liang Shuang. Study on the correlation between GH-IGF-1 axis alteration and cardiovascular risk factors in obese children and discussion on rhGH treatment [D]. Shandong University,2017.

[49] Ren J, Anversa P. The insulin-like growth factor I system: physiological and pathophysiological implication in cardiovascular diseases associated with metabolic syndrome[J]. Biochemical Pharmacology,2015,93(4):409-417.

[50] Zhengxiang H, Lan X, Yin X, et al. The modulatory role of growth hormone in inflammation and macrophage activation[J]. Endocrinology,2022,163(8).

[51] N A S, Marilyn T, A E A, et al. Acromegalic cardiomyopathy: Epidemiology, diagnosis, and management [J]. Clinical cardiology, 2018,41(3):419-425. 

[52] Peter W, Luigi M, Peter K, et al. Acromegalic Cardiomyopathy: An Entity on its own? The Effects of GH and IGF-I Excess and Treatment on Cardiovascular Risk Factors[J]. Archives of medical research, 2023, 54(8):102921-102921.

[53] N R C. Cardiovascular function in acromegaly[J]. Endocrine reviews,2003,24(3):272-7.

[54] Hradec J, Marek J, Kral J, et al. Long-term echocardiographic follow-up of acromegalic heart disease [J]. Am J Cardiol. 1993:72:205.

[55] Epstein FH, Hunter JJ, Chien KR. Signaling Pathways for Cardiac Hypertrophy and Failure[J]. N Engl J Med. 1999:341:1276-83.

[56] E N, A K, N Z, et al. Echocardiographic Myocardial Changes in Acromegaly: a Cross-Sectional Analysis in a Tertiary Center in Bulgaria[J]. Acta endocrinologica (Bucharest, Romania. 2019, 5(1):52-61.

[57] A C, R B, P M, et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy[J]. The Journal of clinical endocrinology and metabolism,2000,85(1):193-9.

[58] Ma Piyong. Effect of growth hormone on cardiomyocyte apoptosis in rats with ischaemic heart failure [D]. Jilin University,2011.

[59] Gabriela Mihai, Márta Korbonits. Chapter-15 Hypertension in growth hormone excess and deficiency. Endocrine Hypertension[M]. Academic press. 2023,217-247

[60] Minniti G, Moroni C, Jaffrain-Rea ML, et al. Prevalence of hypertension in acromegalic patients: clinical measurement versus 24-hour ambulatory blood pressure monitoring[J]. Clin Endocrinol. 1998; 48(2):149-52. 

[61] Fabiola C, Adriana M, F R H, et al. Role of ambulatory blood pressure monitoring in patients with acromegaly[J]. Journal of hypertension,2016,34(7):1357-63.

[62] Chiara S, Claudio U, Martina L, et al. The beneficial effect of acromegaly control on blood pressure values in normotensive patients[J]. Clinical endocrinology,2014,81(4):573-81.

[63] CHEN Jing, GU Feng. Clinical diagnosis and treatment of acromegaly and hypertension[J]. Chinese Journal of Practical Internal Medicine,2009,29(10):887-890.

[64] Peter K, Anne B, Michael F, et al. Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity[J]. The Journal of clinical endocrinology and metabolism, 2011, 96(7):2127-35.

[65] Say V, Peter K, Marie T, et al. Osmotic stress regulates mineralocorticoid receptor expression in a novel aldosterone-sensitive cortical collecting duct cell line[J]. Molecular endocrinology (Baltimore, Md.), 2009,23(12):1948-62.

[66] Peter K, Gherardo M, Marc L, et al. Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications[J]. Endocrine reviews,2014,35(2):234-81.

[67] Ho KY, Weissberger AJ. The antinatriuretic action of biosynthetic human growth hormone in man involves activation of the renin-angiotensin system [J]. Metabolism. 1990 Feb;39(2):133-7.

[68] Møller J, Møller N, Frandsen E, et al. Blockade of the renin-angiotensin-aldosterone system prevents growth hormone-induced fluid retention in humans[J]. Am J Physiol. 1997 May;272(5 Pt1): E803-8.

[69] Bielohuby M, Roemmler J, Manolopoulou J, et al. Chronic growth hormone excess is associated with increased aldosterone: a study in patients with acromegaly and in growth hormone transgenic mice [J]. Exp Biol Med (Maywood). 2009 Aug;234(8):1002-9.

[70] Møller J, Jørgensen JO, Møller N, et al. Expansion of extracellular volume and suppression of atrial natriuretic peptide after growth hormone administration in normal man[J]. J Clin Endocrinol Metab. 1991 Apr;72(4):768-72.

[71] Peter K, Say V, Anne B, et al. Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly[J]. Endocrinology,2008,149(7):3294-305.

[72] M A R, Mónica M. Bringing Cardiovascular Comorbidities in Acromegaly to an Update. How Should We Diagnose and Manage Them? [J]. endocrinology,2019,10120.

[73] Salvatore C, Barbara A, Giovanni C, et al. Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography [J]. The Journal of clinical endocrinology and metabolism,2006,91(10):3766-72.

[74] Hiroyoshi A, Jürgen K, Gerald W, et al. Acromegaly per se does not increase the risk for coronary artery disease[J]. European journal of endocrinology,2010,162(5):879-86.

[75] M O, S K, H Y, et al. Characterisation of premature atherosclerosis of carotid arteries in acromegalic patients [J]. Clinical endocrinology, 2001,54(6):791-6.

[76] Gregorio B, Paolo M, Antonio S, et al. Early vascular alterations in acromegaly[J]. The Journal of clinical endocrinology and metabolism,2002,87 (7):3174-9.

[77] A C, S S, G C, et al. Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly[J]. Clinical endocrinology. 2001,54(4):515-24.

[78] I K, H O, B P, et al. Investigation of early atherosclerotic changes in acromegalic patients[J]. Int J Clin Pract. 2010 Jan;64(1):39-44. 

[79] L C R, S C, V C, et al. Circulating adiponectin levels and cardiovascular risk factors in acromegalic patients[J]. European journal of endocrinology,2004,150(5):663-9.

[80] Tellatin S, Maffei P, Osto E, et al. Coronary microvascular dysfunction may be related to IGF-1 in acromegalic patients and can be restored by therapy [J]. Atherosclerosis,2018,269100-105.

[81] Marques C S S D, B A G L, M C I V, et al. Low risk of coronary artery disease in patients with acromegaly [J]. Endocrine,2015,50(3):749-55.

[82] Annamaria C, Letizia S, Paolo M, et al. High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study[J]. The Journal of clinical endocrinology and metabolism,2003,88(7):3196-201.

[83] M A P, W S T V, R J L, et al. Increased prevalence of regurgitant valvular heart disease in acromegaly [J]. The Journal of clinical endocrinology and metabolism,2004,89(1):71-5.

[84] Klaauw D V A, Bax J, Roelfsema F, et al. Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation[J]. Growth Hormone IGF Research,2006,16(2):101-107.

[85] M P, F D, R V, et al. Electrophysiological features in acromegaly: re-thinking the arrhythmic risk? [J]. Journal of endocrinological investigation Journal of endocrinological investigation ,2020,44(2):1-13.

[86] Kahaly G, Olshausen KV, Mohr-Kahaly S,et al. Arrhythmia profile in acromegaly[J]. Eur Heart J. 1992 Jan;13(1):51-6.

[87] V K M, G E P, V N T, et al. Heart arrhythmias and conduction disorders in patients with acromegaly: the role of cardiac magnetic resonance imaging]. [J]. Terapevticheskii arkhiv,2020,92(10):70-77.

[88] Leila W, Leandro K, Rodrigo S, et al. Low frequency of cardniac arrhythmias and lack of structural heart disease in medically-naïve acromegaly patients: a prospective study a t baseline and after 1 year of somatostatin analogs treatment[J]. Pituitary,2016,19(6):582-589.

[89] A C, F D, C M, et al. Heart rate variability is reduced in acromegaly patients and improved by treatment with somatostatin analogues[J]. Pituitary,.2015,18(4):525-34.

[90] J S, B-A B, T R, et al. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy[J]. The Journal of clinical endocrinology and metabolism, 2004,89(7):3306-12.

[91] M A A, T M H, J P W, et al. Effects of GH replacement on 24-h ambulatory blood pressure and its circadian rhythm in adult GH deficiency[J]. Clinical endocrinology,2002,56(4):431-7.

[92] Patrick M, Simon G, Marc N, et al. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials[J]. The Journal of clinical endocrinology and metabolism,2004,89(5):2192-9.

[93] Cittadini A, Cuocolo A, Merola B, et al. Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement[J]. Am J Physiol. 1994 Aug;267(2 Pt 1): E219-25.

[94] Sanmartí A, Lucas A, Hawkins F, et al. Observational study in adult hypopituitary patients with untreated growth hormone deficiency (ODA study). Socio-economic impact and health status. Collaborative ODA (Observational GH Deficiency in Adults) Group[J]. Eur J Endocrinol. 1999 Nov; 141(5):481-9.

[95] Markussis V, Beshyah SA, Fisher C, et al. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults[J]. Lancet. 1992 Nov 14;340(8829):1188-92.

[96] Amato G, Carella C, Fazio S, et al. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses[J]. J Clin Endocrinol Metab. 1993 Dec;77(6):1671-6.

[97] Díez J, Laviades C. Insulin-like growth factor-1 and cardiac mass in essential hypertension: comparative effects of captopril, lisinopril and quinapril[J]. J Hypertens Suppl. 1994 Jul;12(4): S31-6. 

[98] Annamaria C,Carolina S D ,Rosario P , et al.The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study.[J].The Journal of clinical endocrinology and metabolism,2002,87(3):1088-93.

[99] Longobardi S, Cuocolo A, Merola B, et al. Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiency. [J]. Clin Endocrinol (Oxf). 1998 Feb;48(2):137-43.

[100] A C, A C, C S D, et al. Does the age of onset of growth hormone deficiency affect cardiac performance? A radionuclide angiography study[J]. Clinical Clinical endocrinology,2000,52(4):447-55.

[101] Colao A, Somma D C, Savanelli C M, et al.Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy[J].Growth Hormone IGF Research, 2006, 16(Suppl.A): 41-48.

[102] Chrisoulidou A,Beshyah A S ,Rutherford O , et al. Effects of 7 Years of Growth Hormone Replacement Therapy in Hypopituitary Adults[J]. The Journal of Clinical Endocrinology Metabolism, 2000, 85(10): 3762-3769.

[103] Boschetti M, Agosti S, Albanese V, et al. One-year GH replacement therapy reduces early cardiac target organ damage (TOD) in adult GHD patients[J]. Endocrine. 2017 Feb;55(2):573-581.

[104] Leonsson M, Hulthe J, Johannsson G, et al. Increased Interleukin-6 levels in pituitary-deficient patients are independently related to their carotid intima-media thickness[J]. Clin Endocrinol (Oxf). 2003 Aug; 59(2):242-50.

[105] M A T A, A T E, H B, et al. Recombinant GH replacement in hypopituitary adults improves endothelial cell function and reduces calculated absolute and relative coronary risk[J]. Clinical endocrinology, 2004,61(3):387-93.

[106] ITOH E, HIZUKA N, FUKUDA I, et al. Metabolic Disorders in Adult Growth Hormone Deficiency: a Study of 110 Patients at a Single Institute in Japan[J]. Endocrine Journal,2006,53(4):539-545.

[107] Rosén T, Edén S, Larson G, et al. Cardiovascular risk factors in adult patients with growth hormone deficiency[J]. Acta Endocrinol (Copenh). 1993 Sep;129(3):195-200.

[108] de Boer H, Blok GJ, Voerman HJ, et al. Serum lipid levels in growth hormone-deficient men[J]. Metabolism. 1994 Feb;43(2):199-203. 

[109] Soares A J B, S R M A, Roberto S, et al. Familial isolated growth hormone deficiency is associated with increased systolic blood pressure, central obesity, and dyslipidemia[J]. The Journal of clinical endocrinology and metabolism,2002,87(5):2018-23.

[110] Roger A, Ulla F, F A M, et al. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis[J]. European journal of endocrinology,2006,155(1):79-90.

[111] Attallah H, Friedlander L A, Hoffman R A. Visceral obesity, impaired glucose tolerance, metabolic syndrome, and growth hormone therapy[J]. Growth Hormone IGF Research,2006,1662-67.

[112] Johansson JO, Fowelin J, Landin K, et al. Growth hormone-deficient adults are insulin-resistant[J]. Metabolism. 1995 Sep;44(9):1126-9. 

[113] Gazzaruso C, Gola M, Karamouzis I, et al. Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH--an update[J]. J Clin Endocrinol Metab. 2014 Jan;99(1):18-29.